---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-092058"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2026-08-06T20:29:52+00:00"
generated_at: "2026-08-06T20:32:23.046896+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verastem Q2 net product revenue $25.1M; cash runway extended into H2 2027 via $75M Oberland deal

## Summary
- Net product revenue of $25.1M from AVMAPKI FAKZYNJA CO-PACK, up from $2.1M in Q2 2025.
- Total revenue $40.1M (incl. $15M COPIKTRA milestone); GAAP net loss $34.7M ($0.35/share).
- Cash, equivalents & investments $136.4M; proforma $201.4M after $50M Oberland closing and $15M milestone.
- First patients dosed in all three TARGET-D Phase 2 trials of VS-7375; updated data expected October 2026.
- Appointed Michael P. Bailey to Board of Directors; non-dilutive royalty financing with Oberland Capital.

## SEC filing metadata
- accession: 0001104659-26-092058
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2026-08-06T20:29:52+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465926092058/0001104659-26-092058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465926092058/tm2622452d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-092058
- JSON: https://secwatch.observer/filing/0001104659-26-092058.json
- Plain text: https://secwatch.observer/filing/0001104659-26-092058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.